TOPLINE:
Adding radium-223 dichloride (Ra223) to metastasis-directed stereotactic ablative radiotherapy (SABR) did not improve progression-free survival compared with SABR alone in men with bone-only oligometastatic castration-sensitive prostate cancer, according to a phase 2 trial. However, the authors identified two potential prognostic biomarkers — high-risk DNA mutations and T-cell receptor repertoire diversity — to predict progression-free survival outcomes in patients receiving SABR.
METHODOLOGY:
- Metastasis-directed SABR has demonstrated benefit in oligometastatic castration-sensitive prostate cancer, but disease progression often occurs in bone.
- To assess whether adding Ra223 to SABR would delay disease progression, researchers conducted the multicenter phase 2 RAVENS trial involving 64 men with recurrent…